🧠🩸Advances in Alzheimer’s blood tests in 2025 and what’s coming in 2026! Blood tests for Alzheimer’s disease pathology picked up steam in 2025 and are set to make further advances in transforming the diagnosis and care of patients with cognitive impairment in 2026. Here are my highlights from 2025 and predictions for 2026: 1️⃣ New blood tests 2025: New blood tests including eMTBR-tau243 showed stronger associations with tau neurofibrillary tangles and cognitive symptoms: nature.com/articles/s41591-0… 2026: Studies will examine how to use plasma eMTBR-tau243 and similar analytes to stage Alzheimer’s and refine clinical diagnosis 2️⃣ Improved detection of Alzheimer’s pathology in asymptomatic individuals 2025: Plasma p-tau217 identified cognitively unimpaired individuals with amyloid pathology (jamanetwork.com/journals/jam…) and those at risk of cognitive decline (nature.com/articles/s43587-0…) 2026: Models that incorporate plasma biomarkers including p-tau217 will improve prediction of risk for cognitive impairment with applications in clinical trials 3️⃣ Blood test performance 2025: Meta-analyses demonstrated that p-tau217 measures best classified Alzheimer’s pathology: thelancet.com/journals/laneu…; alz-journals.onlinelibrary.w… 2026: Larger and “real world” datasets will examine the performance of many Alzheimer’s blood tests; tools will improve interpretation by considering multiple cut-off approaches and continuous biomarker levels 4️⃣ Clinician education 2025: Many groups worked to educate specialists on the appropriate use of Alzheimer’s blood tests, including the Alzheimer’s Association, which developed clinical practice guidelines: alz-journals.onlinelibrary.w… 2026: Efforts will intensify to educate specialists and primary care clinicians on the appropriate integration of Alzheimer’s blood tests into holistic clinical care 5️⃣ FDA clearance of Alzheimer’s blood tests 2025: Two tests were cleared by the FDA to support clinical diagnosis of Alzheimer’s: Fujirebio p-tau217/Aβ42 in secondary care (fda.gov/news-events/press-an…); Roche p-tau181 for rule-out of Alzheimer’s in primary care (diagnostics.roche.com/us/en/…) 2026: More tests will achieve regulatory clearances in the US and globally, especially high-performing p-tau217-based tests; legislation and advocacy like the ASAP Act (alz.org/news/2025/house-intr…) will broaden access to cleared blood tests #ENDALZ #AlzheimersDisease #Biomarkers Feel free to add your highlights from 2025 and predictions for 2026. Let’s keep our progress going!